Skip to main content
CorMedix Inc. logo

CorMedix Inc. — Investor Relations & Filings

Ticker · CRMD ISIN · US21900C3088 LEI · 5299006YIA3L0MBW8358 US Manufacturing
Filings indexed 1,001 across all filing types
Latest filing 2023-11-16 Regulatory Filings
Country US United States of America
Listing US CRMD

About CorMedix Inc.

https://cormedix.com/

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening infectious and inflammatory diseases. The company's principal product is DefenCath® (taurolidine and heparin), an antimicrobial and antifungal catheter lock solution. It is approved to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. In addition to DefenCath, CorMedix's early-stage research includes exploring the potential of taurolidine for cancer treatment, particularly in pediatric neuroblastoma, and for other antimicrobial and anti-inflammatory applications.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings
2023-11-16 English
10-Q Filing
Interim / Quarterly Report Q3 2023
2023-11-14 English
8-K Filing
Regulatory Filings
2023-11-14 English
8-K Filing
Regulatory Filings
2023-10-30 English
ARS Filing
Annual Report
2023-09-13 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2023-09-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.